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Objective: Determine if NC001, an oral formulation of nicotine that reduces
levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls,
freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients.
Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs
in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes
helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist,
could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled
65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks,
beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified
Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson’s
Disease Rating Scale (UPDRS).
Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at
baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat
analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30)
had a significant reduction in falls vs. placebo patients (3/27) (p= 0.0041) as assessed by
UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo
patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had
a significant improvement (p = 0.01) in UDysRS ambulation subtest (40% vs. 3%,
respectively). Although NC001 patients had a greater reduction in dyskinesias on the
UDysRS than placebo patients (30% vs. 19%, respectively), this was not significant
(p = 0.09).
Conclusions: NC001 significantly improved two refractory symptoms of PD, falls
and FOG. The reduction in falls and FOG is attributed to selective stimulation of
nicotinic receptors.
Clinical Trial Registration: Conducted under IND 105, 268, serial number 0000.
ClinicalTrials.gov identifier NCT00957918.
Keywords: Dyskinesia, falls, freezing of gait, nicotine, Parkinson disease
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INTRODUCTION
Parkinson disease (PD) is a common and disabling
neurodegenerative disease. Although PD is not curable,
many of its symptoms can be managed by dopaminergic drugs,
principally levodopa. However, as PD progresses, more than 30%
of patients develop freezing of gait (FOG), a sudden, transient,
and often unpredictable inability to walk (1, 2). FOG is often
disabling, leads to falls, and is relatively refractory to levodopa
(1). Advancing PD also causes more than 30% of patients to fall
(3–5). These falls may or may not be associated with FOG (1, 2).
Falls are the main reason PD patients are hospitalized, leading
to high health-care expenses (3, 5). Falls are often refractory
to, and sometimes worsened by, levodopa (6). The dose of
levodopa is generally increased as the disease progresses, which
results in levodopa-induced dyskinesias (LIDs) in at least 30%
of patients (7). LIDs interfere with activities of daily living,
including ambulation.
NC001 (nicotine bitartrate dihydrate, originally named
NP002), a novel, orally administered, direct agonist at central
nervous system cholinergic nicotine receptors, was evaluated in
PD. NC001, like nicotine in cigarettes, results in a rapid, high-
level, selective stimulation of nicotine receptors and may be
neuroprotective (8, 9). Unlike nicotine from cigarettes, NC001 is
uncontaminated by potentially carcinogenic tars and fillers, and,
unlike nicotine in patches and gums, NC001 does not desensitize
nicotinic receptors (8–10). Nicotinic receptors are distributed
throughout the central nervous system with clusters in the
striatum and the pedunculopontine nuclei (PPN) (8–11). Before
the initiation of this study, NC001 was found to reduce LIDs in
monkeys with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP)-induced lesions. Donepezil or rivastigmine, which are
indirect agonists at muscarinic cholinergic receptors, did not
have this effect (8, 10).
In 2009, a study involving 65 patients from 12 centers was
undertaken to evaluate the safety and tolerability of NC001
in patients with PD, and the effectiveness of NC001 on LIDs,
as assessed by the Unified Dyskinesia Rating Scale (UDysRS)
(12), and on rigidity, tremor, and bradykinesia as assessed
by the Unified Parkinson’s Disease Rating Scale (UPDRS)
(ClinicalTrials.gov identifier: NCT00957918) (Figure 1) (13).
The results suggested a modest but nonsignificant reduction in
LIDs and no improvement in rigidity, tremor, or bradykinesia,
symptoms that are usually improved by levodopa. Although the
scales utilized for the original study contain questions pertaining
to falls and FOG, we did not initially analyze these data.
Falls and FOG are symptoms usually not improved by
levodopa (5, 6), leading investigators to study the effects of
other neurotransmitters. Bohnen et al. (14) and Perez-Lloret and
Barrantes (15) have studied the effect of the cholinergic system
on locomotion, postural control, and falls, while Chung et al. (16)
studied the effects of donepezil on reducing falls and Henderson
Abbreviations: CI, confidence interval; DBS, deep-brain stimulation; FOG,
freezing of gait; LID, levodopa-induced dyskinesia; LS, least squares; PD, Parkinson
disease; PPN, pedunculopontine nuclei; UDysRS, Unified Dyskinesia Rating Scale;
UPDRS, Unified Parkinson’s Disease Rating Scale.
et al. (17) studied the effects of rivastigmine in improving
postural control and possibly in reducing falls (but not FOG).
On the basis of our observations of the potential benefits of these
cholinergic drugs in reducing falls, we analyzed our previously
collected data on the effects of orally administered NC001 vs. a
placebo, specifically focusing on falls and FOG in patients with
PD. Because nicotine directly stimulates nicotinic cholinergic
receptors in the central nervous system, we hypothesized that
NC001 would reduce falls and FOG in PD patients.
MATERIALS AND METHODS
Study Design
The original study was a randomized, double-blind, multicenter
study developed to compare NC001 with placebo in adult PD
patients. The study was completed in 12 centers within the
United States. Both private practices and university hospitals
participated in data collection. The study was conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice Guidelines. All sites received approval from an
institutional review board. The clinical trial was conducted under
IND 105, 268, ClinicalTrials.gov identifier NCT00957918. This
paper is a result of a retrospective reanalysis of our data, based on
data from new studies on the effects of indirect-acting cholinergic
agents on falls and FOG.
Patients
Eligible study patients were required to have a diagnosis of
idiopathic PD, to be within a Hoehn and Yahr stage II–IV (13)
while in a peak “on” state (levodopa level in a therapeutic range),
to have been on a stable dose of levodopa for at least 30 days
prior to and throughout the study, to have moderate to severely
disabling LIDs for at least 25% of the waking day as determined
by Questions 32 and 33 in Part IV of the UPDRS (13), and
to have a Mini-Mental State Examination score ≥26. Patients
were excluded from the study if they were active smokers or
had atypical Parkinson disorders; prior deep brain stimulation
(DBS); unstable angina; or a history of ventricular arrhythmias,
active peptic ulcer, schizophrenia, schizoaffective disorder, or
bipolar disease.
Patients were recruited from the practices of the participating
study investigators. There were no advertisements or monetary
inducements to patients. Written informed consent was obtained
from each patient prior to participation.
Randomization and Masking
PD patients were randomly assigned to either the NC001
or placebo group in a 1:1 ratio. Random assignment was
based on a computer-generated process, and investigational
product was distributed based on a randomized number
written on the investigational product container, so as to
avoid unblinding.
The NC001 and placebo were identical in appearance and
packaging. Both nicotine bitartrate dehydrate and placebo were
manufactured by Siegfried Ltd. (Zofingen, Switzerland) and were
packaged, tested for clinical use, and monitored for stability
in accordance with current Good Manufacturing Practices by
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FIGURE 1 | Trial profile. The number of patients screened and enrolled in the study, as well as the number of patients who left the study at each point and the reasons
for exclusion from the study, with the resulting number left enrolled, are shown. All patients who completed at least one postbaseline visit were included in the
intention-to-treat analysis, which is also documented in the figure. Used with permission from Barrow Neurological Institute, Phoenix, Arizona.
UPM Pharmaceuticals (Baltimore, Maryland, USA). All patients,
study site personnel, raters, and the sponsor were blinded to
treatment assignment. Active drug and placebo were identical
in shape, color, weight, appearance, and dissolvability. Packaging
was identical.
Procedures
The duration of the study was 17 weeks, including 10 weeks
of active treatment with NC001 or placebo, a transition period
(3 weeks), and a posttreatment period (4 weeks). The drug or
placebo was self-administered orally 4 times daily in a blinded
fashion. Patients were examined at each visit as described below
(see Outcomes) while in an “on” state, when levodopa was in a
therapeutic range. During the treatment phase, dosing was begun
at 1mg every 6 h (total daily dose of 4 mg/day) at the time of the
baseline visit and escalated upward at 2-week intervals as follows:
2mg every 6 h at visit one (8 mg/day); 4mg every 6 h at visit
two (16 mg/day); and 6mg every 6 h at visit three (24 mg/day).
Patients were maintained on 24 mg/day for 4 weeks.
Outcomes
The primary outcomes in the original study were changes from
baseline to week 10 in UPDRS and UDysRS scores by treatment
group. In our reanalysis, questions from the original UPDRS Part
II (Activities of Daily Living, Questions 13 and 14) and Part III
(Motor Examination, Item 30, the “pull test,” a test of postural
stability) were compared to assess for treatment effects on falls
and FOG after administration of NC001 or placebo. LIDs before
and after treatment were assessed with the UDysRS (12) during
both analyses. Evaluations during transition and posttreatment
periods were identical to those during the treatment phase.
Compliance was checked with serum cotinine levels
(cotinine is a metabolite of nicotine). Nicotine withdrawal
symptoms were treated after completion of the active trial
and again after completion of the posttreatment period
utilizing the Nicotine Withdrawal Symptom Assessment (18).
Adverse events potentially related to treatment were reported
by frequency.
Statistical Analysis
All hypotheses were tested using 2-sided tests with alpha
set at the 0.05 level of significance. In general, efficacy data
were summarized by treatment group, and safety data were
summarized by treatment group and for the overall study
population. In all analyses, assumptions such as normality and
homogeneity of variance were examined before conducting the
proposed parametric statistical procedures. Categorical variables
were analyzed by Fisher exact 2-tailed tests and continuous
variables were tested under 2-sample t-tests. The equality of
variances was examined using an F-test before applying the 2-
sample t-test. The t-test statistics were adjusted if the variances
between groups were significantly unequal.
The modified intent-to-treat population comprised all
patients who were in the randomized population, took at least
1 dose of the study medication, and had a baseline and at least
1 scheduled postbaseline assessment. The efficacy analyses were
conducted using this population. The intent-to-treat population
consisted of all subjects who were in the randomized population
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who took at least 1 dose of study medication. This population
was used only for the post hoc sensitivity analysis.
Sample size calculations were based on the following
assumptions: type I error of α = 0.05, power = 70%, 1-sided
test, placebo response rate = 36.8%, and a 30% improvement
in response compared to placebo. Initial protocol power
calculations were based on a standard formula for power in 2
× 2 tables using Stata v10.1. The calculations were confirmed
by using a 2-group chi-square test of equal proportions using N-
Query Advisor 6.01. The calculations showed that, when using a
1-sided test, 25 evaluable subjects per arm would provide a 70%
chance of detecting a difference between placebo and NC001.
For falls (UPDRS Part II, Question 13), a 5-point scale was
used: 0=no falls to 4=falls more than once per day. For FOG
and falls related to FOG (UPDRS Part II, Question 14), a 5-
point scale was used: 0=no FOG to 4=frequent falls from FOG.
Retropulsion, which assesses postural control by the pull test
(UPDRS Part III, Item 30) on a 5-point scale from 0 to 4, was also
compared betweenNC001 and placebo patients. A comparison of
distributions between the NC001 and placebo groups was made
using a distribution that ranged from−3 (a 3-point improvement
on the 5-point scale) to +3 (a 3-point worsening on the 5-point
scale). Analyses were made with the Fisher exact 2-tailed test.
Improvement or worsening over baseline was calculated from the
last treatment visit (19).
The efficacy variables for LIDs were the mean change
from baseline to week 10 in the UDysRS total score and
UDysRS subscores. An analysis of covariance combined features
of regression and analysis of variance. Exploratory analyses
of continuous outcomes using a mixed-effect model repeated
measures method were performed on the modified intent-to-
treat population in conjunction with the analysis of covariance
model to assess the sensitivity of the data to different analysis
methods. Post hoc sensitivity analyses were done on the intent-to-
treat population using both the analysis of covariance andmixed-
effect model repeated measures methods. In addition to the
descriptive summary of each variable from baseline to end point,
least-squares (LS) means, standard errors, and 95% confidence
intervals (CI) of each group, and the difference of LS means
between the 2 treatment groups and its 95% CI are presented.
A similar analysis was applied to comparisons between UPDRS
Part II and UPDRS Part III.
The original study was overseen by a data monitoring
company, i3, a contract research organization located in Basking
Ridge, New Jersey, USA.
Role of the Funding Source
The sponsor of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the
report. The corresponding author had full access to all the data in
the study and had final responsibility for the decision to submit.
RESULTS
Study recruitment proceeded from September 30, 2009, to
September 19, 2010. Eighty-five participants were assessed for
eligibility, and 20 were determined to be ineligible for the study.
Sixty-five patients were randomized: 35 to NC001 and 30 to
placebo. For falls, FOG, and retropulsion, 30 NC001 and 27
placebo patients had sufficient data to be analyzed. Over the
course of the study, 10 patients assigned to the NC001 group
and 7 assigned to the placebo group dropped out of the study.
All patients who participated in at least 1 postbaseline visit were
included in the statistical analysis, 30 NC001 patients and 27
placebo patients. The demographics of all 65 patients recruited
at baseline are summarized in Table 1.
The changes in UPDRS Part II and III scores from baseline
to 10 weeks (i.e., posttreatment) were compared between NC001
and placebo patients. No significant differences were found after
treatment between the NC001 and placebo groups for either Part
II or Part III (p ≥ 0.34) (Table 2).
Scores by treatment group for UPDRS Part II Questions
13 and 14 and Part III Item 30, the pull test, were compared
separately (Table 3). Fourteen of 30 (47%) NC001 patients had
a reduction in falls. In contrast, only 3 of 27 (11%) placebo
patients had a reduction in falls. This difference was statistically
significant (p = 0.0043). The difference in reduction of FOG
was also significant (p = 0.0041) between groups, with 12 of 30
(40%) NC001 patients and 4 of 27 (15%) placebo patients having
a reduction in FOG. Similarly, 10 of 30 (33%) NC001 patients had
a reduction in retropulsion, the pull test, compared to only 2 of
27 (7%) placebo patients (p= 0.02).
On the UDysRS ambulation subtest score, NC001 patients
had a 46% reduction (i.e., improvement) in the effect of LIDs
on ambulation (9.5 ± 6.0 at baseline to 5.1 ± 5.3 at week 10)
while placebo patients had a 3% reduction (7.6 ± 5.0 at baseline
to 7.4 ± 5.7 at week 10). This difference was significant in favor
of NC001 (p = 0.01). On the total UDysRS, the main measure
of LIDs change, there was a 29% reduction in LIDs among
patients receiving NC001 (51.7 ± 16.9 at baseline to 36.4 ± 16.1
at week 10) and a 19% reduction among patients on placebo
(48.1 ± 15.0 at baseline to 38.8 ± 19.0 at week 10). Although
TABLE 1 | Baseline characteristics of the modified intent-to-treat population.
NC001 (n = 35) Placebo (n = 30) P-Value
Sex 0.22
Male 14 (40.0%) 17 (56.7%)
Female 21 (60.0%) 13 (43.3%)
Age (years) 68.1 ± 8.3 65.5 ± 7.2 0.18
Ethnic origin 0.78
White 33 (94.3%) 28 (93.3%)
Black 1 (2.9%) 0 (0.0%)
Asian 1 (2.9%) 2 (6.7%)
PD duration (years) 11.2 ± 4.7 11.1 ± 5.6 0.93
Levodopa duration (years) 9.6 ± 4.7 10.2 ± 5.4 0.66
LIDs duration (years) 5.3 ± 3.3 5.2 ± 3.2 0.97
Levodopa dose (mg/day) 612 ± 201 582 ± 180 0.70
Hoehn and Yahr stage 2.52 ± 0.57 2.38 ± 0.48 0.97
Data are n (%) or least-squares means ± SE. PD, Parkinson disease; LIDs, levodopa-
induced dyskinesias. P-values for NC001 vs. placebo groups calculated using 2-sample
t tests.
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TABLE 2 | Comparison by treatment group of mean UPDRS Part II and Part III scores before and after treatment.
UPDRS II UPDRS III
(Activities of daily living) (Motor examination)
NC001 Placebo NC001 Placebo
LS means ± SE*
Baseline 13.1 ± 6.0 11.4 ± 5.3 20.0 ± 8.8 16.9 ± 8.3
Week 10 10.1 ± 5.3 8.8 ± 5.0 17.3 ± 10.6 16.8 ± 8.6
Change 2.8 ± 5.2 2.7 ± 4.5 2.0 ± 7.5 −0.4 ± 6.5
NC001 vs. placebo†
Difference in LS means ± SE (95% CI) 10.1 ± 0.96 (6.9–12.1) −18.3 ± 1.8 (−24.1 to −16.3)
P-value 0.63 0.34
*At baseline, n = 35 NC001 patients and n = 30 placebo patients. At 10 weeks, n = 30 NC001 patients and n = 27 placebo patients.
†
Comparison of baseline to week 10. LS, least squares; UPDRS, Unified Parkinson’s Disease Rating Scale.
TABLE 3 | Change by treatment group in specific UPDRS scores before and after
treatment.*
Change in score: baseline to week 10
(no. of patients)




NC001 14/30 (47%) 2 5 7 15 1 0 0
Placebo 3/27 (11%) 0 0 3 23 1 0 0
P-value† 0.0041
FOG
NC001 12/30 (40%) 0 2 10 17 1 0 0
Placebo 4/27 (15%) 0 1 3 20 2 1 0
P-value† 0.0043
Pull Test
NC001 10/30 (33%) 0 5 5 19 1 0 0
Placebo 2/27 (7%) 0 0 2 24 1 0 0
P-value† 0.02
*UPDRS Part II Question 13 assesses falls unrelated to freezing of gait (FOG), Part
II Question 14 assesses FOG, and Part III Item 30 assesses retropulsion (pull test).
Improvement is represented as a - (negative) or decrease in falls or FOG. The number
of patients included everyone who had a baseline and at least 1 postbaseline visit.
†
Change in NC001 and placebo patient groups scores were compared using a Fisher
exact 2-tailed test. UPDRS, Unified Parkinson’s Disease Rating Scale.
the percentage reduction in total UDysRS favored NC001, the
difference between groups did not reach statistical significance
(p= 0.09) (Table 4).
No nicotine withdrawal symptoms were noted for patients
on NC001 or placebo. Serum cotinine levels paralleled dosing of
nicotine in NC001 patients and were absent in placebo patients.
The most frequently seen adverse events are reported in Table 5.
The most common adverse event among NC001 patients was
nausea (13/35, 37.1%). This generally resolved spontaneously
or with ondansetron. The most common adverse event among
placebo patients was insomnia (3/30, 10.0%). More adverse
events (45 events) were reported among NC001 than placebo
patients (14 events). Eleven patients withdrew because of adverse
events, 6 who were on NC001 and 5 who were on placebo.
DISCUSSION
The study demonstrated that NC001 administered for 10
weeks, when compared to placebo, significantly reduced falls
(p= 0.0043) and FOG (p= 0.0041) independently in PD patients.
Falls and FOG are among the most debilitating consequences of
PD (2–5). No current treatment has been shown to consistently
reduce both falls and FOG. Chung et al. (16) demonstrated a
reduction in falls using donepezil. They enrolled 23 patients
who reported falling at least twice per week in a double-
blind crossover trial. Fall frequency on placebo was 0.25 ±
0.08 per day vs. 0.13 ± 0.03 for patients on donepezil (p <
0.05). Henderson et al. (17) demonstrated an improvement in
locomotion (dynamic stability) but not a reduction in falls in
patients on rivastigmine. Neither of these studies mentioned
FOG. Donepezil and rivastigmine are indirect cholinomimetics,
releasing acetyl choline at muscarinic receptors. Antimuscarinic
drugs increase FOG (9, 15), but it is unknown whether
muscarinic drugs reduce FOG. NC001 is a direct agonist at
nicotinic receptors. This selectivity may account for the beneficial
effects of NC001 on both falls and FOG.
Cholinergic activity is reduced in PD, and this reduction
appears to be closely linked to falls (14–17). Perez-Lloret and
Barrantes (15) studied 17 fallers and 27 non-fallers with PD
with PET scans utilizing [11C] methyl-4-piperidinyl propionate
acetyl-cholinesterase (a marker for cholinergic activity) and [11C]
dihydro-tetrabenazine vesicular monoamine transporter type (a
marker for dopaminergic activity). Cholinergic activity was lower
only in fallers. Dopaminergic activity did not change between
fallers and non-fallers, which implied that falls are mainly caused
by reduced cholinergic activity. NC001 reduced falls and FOG,
we believe, through a direct effect on nicotinic receptors on
cholinergic neurons (9, 15, 20–23).
It is hypothesized that this effect was primarily active within
the PPN. The PPN has rich connections to the substantia nigra
reticulata, the subthalamic nucleus, and the primary motor
and premotor cortices (9, 16, 21, 24) and is affected in PD,
showing a progressive loss of cholinergic neurons (21–23).
Karachi et al. (25) demonstrated that, in primates with an intact
dopaminergic system, bilateral lesions of the PPN resulted in
marked deficits in locomotion and postural control. Bensaid et al.
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TABLE 4 | Comparison of LS mean ± SE Unified Dyskinesia Rating Scale (UDysRS) scores before and after treatment by treatment group.
NC001 patients Placebo patients Difference in
LS means
at week 10Baseline (n = 30) Week 10 (n = 27) Baseline (n = 27) Week 10 (n = 24) 95% CI P-value
Evaluation of dyskinesias on:
7 body parts 13.5 ± 5.4 8.5 ± 5.4 12.7 ± 4.9 10.3 ± 6.1 −2.8 ± 2.6 −5.7 to 0.1 0.06
Communication 10.5 ± 4.8 7.0 ± 5.0 9.4 ± 5.2 8.2 ± 5.7 −1.9 ± 1.4 −4.7 to 0.9 0.19
Drinking 9.1 ± 5.6 5.3 ± 5.0 7.8 ± 5.4 7.0 ± 5.1 −2.4 ± 1.7 −5.8 to 1.0 0.17
Dressing 11.3 ± 6.2 6.9 ± 5.5 11.1 ± 5.1 8.7 ± 5.4 −2.1 ± 1.4 −5.0 to 0.7 0.14
Ambulation 9.5 ± 6.0 5.1 ± 5.3 7.6 ± 5.0 7.4 ± 5.7 −3.7 ± 1.9 −6.5 to −0.9 0.01
Total UDysRS score 51.7 ± 16.9 36.4 ± 16.1 48.1 ± 15.0 38.8 ± 19.0 −6.7 ± 4.1 −14.7 to −1.3 0.09
Part 1A UDysRS is a patient assessment of duration and severity of dyskinesia. This was replaced by UPDRS Part IV Questions 32-33. Part 1B UDysRS is a patient assessment of the
impact of dyskinesia on ADLs. This was replaced by the Lang-Fahn ADL Dyskinesia Scale. Part 2A UDysRS assesses time in “off”-dystonia. This was not included in the UDysRS total.
Part 2B UDysRS assesses impact of “off” dystonia. No significant differences were noted after 10 weeks of treatment from baseline between NC001 and placebo. Part 2B was not
included in the UDysRS total. Part 3 UDysRS is a physician assessment of impact of dyskinesia on 7 body parts: face, neck, both arms and legs, and trunk and a physician assessment
of the impact of dyskinesia on communication, drinking from a cup, dressing, and ambulation. Bold value indicates statistical significance. LS, least squares.
TABLE 5 | Adverse events (AEs) among patients receiving NC001 or placebo.
AE No. (%) of patients
NC001 (N = 35) Placebo (N = 30)
Any AE 26 (74.3) 14 (46.7)
Nausea 13 (37.1) 2 (6.7)
Dizziness 7 (20.0) 1 (3.3)
Constipation 5 (14.3) 1 (3.3)
Vomiting 4 (11.4) 0 (0.0)
Fatigue 3 (8.6) 0 (0.0)
Pain 3 (8.6) 0 (0.0)
Diarrhea 2 (5.7) 1 (3.3)
Headache 2 (5.7) 1 (3.3)
Pain in extremity 2 (5.7) 0 (0.0)
Tremor 2 (5.7) 0 (0.0)
Nightmare 2 (5.7) 0 (0.0)
Insomnia 0 (0.0) 3 (10.0)
Eleven patients withdrew because of adverse effects: 6 NC001 patients, 5
placebo patients.
(23) demonstrated in primates that cholinergic and dopaminergic
interactions, including those in the PPN, are important and
suggested that, although each transmitter has different functions,
both are needed for postural control and locomotion (20).
Human studies have also linked loss of PPN cholinergic neurons
to disability in PD (9, 21, 22, 24). The PPN is pivotal in scaling
movement to proprioceptive and vestibular inputs and may be
pivotal in reducing falls and FOG (22). The literature suggests
that medically refractory falls and FOG can improve with DBS of
the PPN (26).
NC001 also may have induced a reduction in falls and
FOG by reducing LIDs. Although we believe the reduction is
related to an improvement in postural control, as demonstrated
by improvement in the pull test, further study is needed
to demonstrate this mechanism. A study in which patients
experiencing falls and/or FOG are quantitatively studied during
standing, gait initiation, and locomotion could resolve this
question. Such quantitative data can be collected with inertial
measurement units, kinematic motion capture systems, force
plates, and surface electromyography. Whatever the mechanism,
effectiveness in reducing falls and FOG would be a major step
forward in the treatment of PD.
The effect of NC001 on LIDs was mixed. NC001 decreased
the UDysRS total score by 29% vs. 19% for those on placebo and
significantly decreased the scores regarding the effect of LIDs on
ambulation (p = 0.01). The effect of NC001 on LIDs was not
as robust as the effect reported for extended-release amantadine
(27). However, amantadine was not shown, in a double-blind
study, to reduce falls or FOG. Given the debilitating effects of
LIDs in many patients, the fact that amantadine is the only drug
available to treat LIDs, and that amantadine does not reduce
LIDs in all patients, there appears to be a role for NC001 in
treating LIDs.
It is important to note the limitations of the results of
this study. Because this study was a retrospective reanalysis of
previously collected data, which focused on LIDs instead of falls
or FOG, subjects were not randomized on the basis of falls or
FOG. At the time of the original study, best practices were self-
reporting of falls and FOG. In retrospect, we find that there
are limitations to such self-reporting. This study provides only
exploratory, proof-of-concept data, and a future study to analyze
actual changes in falls and FOG while patients are on NC001 is
needed. The short duration of the study (10 weeks) is a limitation,
as this time period may be insufficient to demonstrate long-
term reductions in falls and FOG. Future studies will rely on
force plates, motion capture systems, and inertial measurement
units that can record the quantitative features of balance and gait
parameters, FOG, and falls in real time.
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